Overview

Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer

Status:
Unknown status

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

gastric cancer is a highly aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the 5-year survival of neoadjuvant S1, oxaliplatin, and docetaxel (SLOT) versus S1, oxaliplatin(SOX) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Treatments:

Docetaxel
Oxaliplatin